Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + paclitaxel vs gemcitabine after FOLFIRINOX failure in metastatic pancreatic ductal adenocarcinoma
2018-002886-21Phase 3Completed
- Sponsor
- Unicancer
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in pancreatic adenocarcinoma (PDAC) comparing Gemcitabine + solvent-based paclitaxel with Gemcitabine alone (2 arms). Primary endpoint: Overall survival. Started Oct 2018; status: completed.
02
Drugs
gemcitabinepaclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2018-002886-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002886-21.